Pay in 4 interest-free payments of $8.75 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib
Neuville S
In the human CLL NSG xenograft model
Paulsen JE
10(3):318-323
SSR128129E - CAS# 848318-25-2 272 The novel Aurora A kinaseSSR128129E (SSR), CAS No. 848318 25 2, is an potent FGFR inhibitor, which inhibits fibroblast growth factor receptor (FGFR) signaling by binding to the extracellular FGFR domain without affecting orthosteric FGF binding. SSR128129E exhibits allosteric properties, including probe dependence, signaling bias, and ceiling effects. Inhibition by SSR128129E is highly conserved throughout the animal kingdom. Oral delivery of SSR128129E inhibits arthritis and
US$ 1994.00
US$ 119.99